CorNova, Inc. (CorNova), a endovascular products company, has announced the election of Andrew T. Jay to the company’s board of directors. Jay is the managing partner of the Medical Solutions Fund of Siemens Venture Capital GmbH (Siemens Venture). Before joining Siemens Venture, he was an Institutional Investor-ranked medical technology analyst with both Alex.

Brown and Wachovia Securities, where his coverage included cardiovascular device companies. Jay received his D.M.D. from the University of Pennsylvania and his M.B.A. from the Kellogg School at Northwestern. He earned his B.S. from Rensselaer Polytechnic Institute.

“Adding such an accomplished and experienced venture investor and medical technology analyst to our board is an important step in the development of CorNova,” said S. Eric Ryan, CorNova’s chief executive officer. “His advice will be invaluable as our company advances our FiberHalo(TM) angioplasty catheter toward commercialization, and we move forward to CE-Mark approval for our Valecor Platinum(TM) Coronary Stent System.”

“CorNova’s FiberHalo catheter and Valecor Platinum Coronary Stent System address two separate billion dollar market opportunities with approaches that could sell well on their own or shift market share significantly in the hands of a major player in the cardiovascular space,” said Jay. He is taking this role independent of his activity at Siemens Venture.